title: Successful TRPV1 antagonist treatment for cardiac hypertrophy and heart failure in mice.
abstract: Heart failure is becoming a global epidemic. It exerts a staggering toll on quality of life, and substantial medical and economic impact. In a pre-clinical model of cardiac hypertrophy and heart failure, we were able to overcome loss of heart function by administering the TRPV1 antagonist BCTC (4-(3-Chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-1-piperazinecarboxamide). The results presented here identify TRPV1 antagonists as new treatment options for cardiac hypertrophy and heart failure.
authors.affiliation: Laboratory of Experimental Medicine, Department of Cell and Molecular Biology, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, USA.
authors.forename: Jaime S
authors.initials: JS
authors.lastname: Horton
authors.forename: Cadie L
authors.initials: CL
authors.lastname: Buckley
authors.forename: Alexander J
authors.initials: AJ
authors.lastname: Stokes
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D006332:Cardiomegaly / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology; D004195:Disease Models, Animal; D006333:Heart Failure / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000235:genetics / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D020097:Natriuretic Peptide, Brain / Q000235:genetics / Q000378:metabolism; D011719:Pyrazines / Q000008:administration & dosage*; D011725:Pyridines / Q000008:administration & dosage*; D050916:TRPV Cation Channels / Q000037:antagonists & inhibitors*
chemical_list: C475772:N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carboxamide; D011719:Pyrazines; D011725:Pyridines; D050916:TRPV Cation Channels; C493921:TRPV1 protein, mouse; D020097:Natriuretic Peptide, Brain; D020780:Matrix Metalloproteinase 9